Literature DB >> 27020243

Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease.

Pablo Miranda-García1, María Chaparro2, Javier P Gisbert2.   

Abstract

BACKGROUND/AIMS: Endoscopy is the gold standard for assessing disease severity in inflammatory bowel disease (IBD), although it is an invasive procedure. Biological markers have been routinely used as a non-invasive means of determining disease activity. The aim of this study was to determine the correlation between common biological markers and endoscopic activity in IBD.
METHODS: Consecutive patients with IBD were included. Serum concentrations of different biomarkers (C-reactive protein [CRP], orosomucoid [ORM], erythrocyte sedimentation rate [ESR], fibrinogen, platelets, leukocytes, neutrophils and hemoglobin [Hb]) were measured, and their accuracy in detecting endoscopic activity was determined.
RESULTS: Eighty patients were included (mean age 46 years, 53% Crohn's disease), 70% with endoscopic activity. Among Crohn's disease patients, 24% had mild endoscopic activity, 12% moderate activity and 39% severe activity. Among ulcerative colitis patients, 35% had an endoscopic Mayo score of 0-1 points, 30% 2 points and 35% 3 points. None of the biomarkers included had a good correlation with endoscopic activity (Area Under the ROC curve [AUC]<0.70) in ulcerative colitis. ORM, fibrinogen and platelets had the best accuracy to detect endoscopic activity in Crohn's disease (AUC: 0.80-0.085). A sub-analysis in postoperative Crohn's disease patients found no correlation between endoscopic recurrence and biomarkers (AUC<0.70).
CONCLUSION: Serological biomarkers, including CRP, have low accuracy to detect endoscopic activity in ulcerative colitis and postoperative Crohn's disease. ORM, fibrinogen and platelets have the best accuracy to detect endoscopic activity in Crohn's disease.
Copyright © 2016 Elsevier España, S.L.U. y AEEH y AEG. All rights reserved.

Entities:  

Keywords:  Actividad endoscópica; C-reactive protein; Cicatrización de la mucosa; Colitis ulcerosa; Crohn's disease; Endoscopic activity; Enfermedad de Crohn; Mucosal healing; Proteína C reactiva; Ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27020243     DOI: 10.1016/j.gastrohep.2016.01.015

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  13 in total

1.  A prospective single centre pilot evaluation of a serum calprotectin assay in unselected GI patients.

Authors:  Rebecca K McCann; Karen Smith; Daniel R Gaya
Journal:  Clin Biochem       Date:  2017-01-16       Impact factor: 3.281

2.  Systematic review: outcomes and adverse events from randomised trials in Crohn's disease.

Authors:  Heather Catt; Dyfrig Hughes; Jamie J Kirkham; Keith Bodger
Journal:  Aliment Pharmacol Ther       Date:  2019-03-03       Impact factor: 8.171

3.  Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn's Disease Exacerbations.

Authors:  Marjolein A Y Klaassen; Floris Imhann; Valerie Collij; Jingyuan Fu; Cisca Wijmenga; Alexandra Zhernakova; Gerard Dijkstra; Eleonora A M Festen; Ranko Gacesa; Arnau Vich Vila; Rinse K Weersma
Journal:  J Crohns Colitis       Date:  2019-10-28       Impact factor: 9.071

4.  Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease.

Authors:  Walter Reinisch; Krisztina Gecse; Jonas Halfvarson; Peter M Irving; Jørgen Jahnsen; Laurent Peyrin-Biroulet; Gerhard Rogler; Stefan Schreiber; Silvio Danese
Journal:  Inflamm Bowel Dis       Date:  2021-01-01       Impact factor: 5.325

5.  Characterization of Crohn's disease patients in Egypt: Risk factors for postoperative recurrence (A cohort study).

Authors:  Shimaa Kamel; Mohamed Sakr; Waleed Hamed; Mohamed Eltabbakh; Ahmed Sherief; Heba Rashad; Yasser Elghamrini; Ahmed Elbaz
Journal:  Ann Med Surg (Lond)       Date:  2021-09-06

Review 6.  Risk factors for postoperative recurrence of Crohn's disease with emphasis on surgical predictors.

Authors:  Antonios Gklavas; Dionysios Dellaportas; Ioannis Papaconstantinou
Journal:  Ann Gastroenterol       Date:  2017-09-26

7.  Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis.

Authors:  Mayu Uchihara; Jun Kato; Saya Tsuda; Takeichi Yoshida; Takao Maekita; Mikitaka Iguchi; Masayuki Kitano
Journal:  JGH Open       Date:  2017-11-01

8.  Association between platelet count and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study.

Authors:  Shinya Furukawa; Sen Yagi; Kana Shiraishi; Kenichirou Mori; Tomoyuki Ninomiya; Keitarou Kawasaki; Yuji Mizukami; Seiyuu Suzuki; Masayoshi Uraoka; Naozumi Shibata; Sanae Nakamura; Satoshi Imamine; Hidehiro Murakami; Katsuhisa Ohashi; Masamoto Torisu; Aki Hasebe; Harumi Yano; Masato Murakami; Eiji Takeshita; Yoshio Ikeda; Yoichi Hiasa
Journal:  BMC Gastroenterol       Date:  2020-11-16       Impact factor: 3.067

9.  Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.

Authors:  Ana Martínez-Feito; Luz Yadira Bravo-Gallego; Borja Hernández-Breijo; Jesús Diez; Laura García-Ramirez; Marta Jaquotot; Chamaida Plasencia-Rodríguez; Pilar Nozal; Araceli Mezcua; María Dolores Martín-Arranz; Dora Pascual-Salcedo
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

10.  A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.

Authors:  R Gacesa; A Vich Vila; V Collij; Z Mujagic; A Kurilshikov; M D Voskuil; E A M Festen; C Wijmenga; D M A E Jonkers; G Dijkstra; J Fu; A Zhernakova; F Imhann; R K Weersma
Journal:  Gut Microbes       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.